Biosimilar therapy for ERBB2 (HER2)-positive breast cancer: Close enough?

JAMA - Journal of the American Medical Association

Volumn 317, Issue 1, 2017, Pages 30-32

  Burstein, Harold J ^a   Schrag, Deborah ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CANCER VACCINE; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; PERTUZUMAB; RECOMBINANT DNA; TRASTUZUMAB; BIOSIMILAR AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BIOLOGICAL THERAPY; BIOSIMILAR THERAPY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL THERAPY; DEVELOPING COUNTRY; DRUG COST; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; EUROPEAN MEDICINES AGENCY; EVIDENCE BASED NURSING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MEDICARE; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; SURVIVAL RATE; UNITED STATES; BREAST TUMOR;

BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; HUMANS; RECEPTOR, ERBB-2;

EID: 85008394537     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.18979     Document Type: Editorial

References (12)

1. Sheingold S, Marchetti-Bowick E, Nguyen N, Yabroff KR. Medicare Part B drugs: pricing and initiatives. March 8, 2016. https://aspe.hhs.gov /sites/default/files/pdf/187581/PartBDrug.pdf. Accessed November 15, 2016.
2. US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. April 2015. http://www.fda.gov/downloads/drugs/guideancecomplianceregulatoryinformation/guidances/ucm291128.pdf. Accessed November 3, 2016.
3. Rugo HS, Barve A,Waller CF, et al; Heritage Study Investigators. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positivemetastatic breast cancer: a randomized clinical trial. JAMA. doi:10.1001/jama.2016.18305
4. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25): 3366-3373.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11): 783-792.
6. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19): 4265-4274.
7. Centers for Disease Control and Prevention. Global cancer statistics: number of cases, deaths, and survivors, 2012. February 2, 2015. http://www.cdc.gov/cancer/international/statistics.htm. Accessed November 15, 2016.
8. World Health Organization. 19th WHO model list of essential medicines. April 2015. http://www.who.int/medicines/publications/essentialmedicines/EML2015-8-May-15.pdf. Accessed November 15, 2016.
9. Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33(14):1574-1583.
10. Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel formetastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
11. Rschoff J, HannaW, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-650.
12. Centers for Medicare & Medicaid Services. Part B biosimilar biological product payment and required modifiers. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/Part-B-Biosimilar-Biological-Product-Payment.html. Accessed November 15, 2016.